Literature DB >> 55413

Aglycosylantibody. Effects of exoglycosidase treatments on autochthonous antibody survival time in the circulation.

J L Winkelhake, G L Nicolson.   

Abstract

Rabbit anti-hapten antibodies were purified by affinity chromatography and characterized immunochemical for in vivo studies of their blood clearance rate and organ distribution after treatment with various glycosidases. Following sequential removal of sialic acid, galactose, and N-acetylglucosamine with the appropriate cellulose-immobilized exoglycosidases, the antibody populations were recharacterized, radiolabeled, and introduced intravenously into the original animals. Using double radioiodine lables it was possible to demonstrate alterations in purified antibody survival times in the circulation and altered organ distribution after glycolytic cleavage. Removal of terminal sialic acid resulted in rapid blood clearance and enhanced localization of asialoantibody in the liver. Subsequent removal of penultimate galactose residues returned both antibody survival time in the circulation and organ distribution to near normal. Removal of subpenultimate N-acetylglucosamine moieties resulted in aglycosylantibody survival values which were intermediate between asialo- and asialoagalactoantibodies. Removal of the three saccharide also increased kidney localization. The results are evaluated based on current concepts of the biological roles of protein-linked carbohydrate and plasma glycoprotein survival time in the circulation.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 55413

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  Recognition of human urine alpha-N-acetylglucosaminidase by rat hepatocytes. Involvement of receptors specific for galactose, mannose 6-phosphate and mannose.

Authors:  K Ullrich; R Basner; V Gieselmann; K Von Figura
Journal:  Biochem J       Date:  1979-05-15       Impact factor: 3.857

2.  Immunological block to mammalian fertilization: survival and organ distribution of immunoglobulin which inhibits fertilization in vivo.

Authors:  R Yanagimachi; J Winkelhake; G L Nicolson
Journal:  Proc Natl Acad Sci U S A       Date:  1976-07       Impact factor: 11.205

3.  Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages.

Authors:  P D Stahl; J S Rodman; M J Miller; P H Schlesinger
Journal:  Proc Natl Acad Sci U S A       Date:  1978-03       Impact factor: 11.205

Review 4.  [Biology of lectins and their application in clinical biochemistry (author's transl)].

Authors:  E Köttgen
Journal:  Klin Wochenschr       Date:  1977-04-15

5.  [Glycoproteins: their biological and clinical significance. II (author's transl)].

Authors:  E Köttgen; C Bauer; W Reutter; W Gerok
Journal:  Klin Wochenschr       Date:  1979-03-01

6.  Mitogen- and alloantigen-stimulated blastogenic responses of dinitrophenyl-modified human lymphocytes.

Authors:  R F Barth; J J O'Hara; R J Duquesnoy; S N Chen; J L Winklehake
Journal:  Immunology       Date:  1982-11       Impact factor: 7.397

7.  Both VH and VL chains of polyreactive IgM antibody are required for polyreactivity: expression of Fab in Escherichia coli.

Authors:  S C Cheung; S Takeda; A L Notkins
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

8.  The antigenicity of asialylated IgG: its relationship to rheumatoid factor.

Authors:  M D Dodon; G A Quash
Journal:  Immunology       Date:  1981-03       Impact factor: 7.397

9.  Modulation of a glycoprotein recognition system on rat hepatic endothelial cells by glucose and diabetes mellitus.

Authors:  J A Summerfield; J Vergalla; E A Jones
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

10.  Evidence for lysosomal enzyme recognition by human fibroblasts via a phosphorylated carbohydrate moiety.

Authors:  K Ullrich; G Mersmann; E Weber; K Von Figura
Journal:  Biochem J       Date:  1978-03-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.